Antibody-inspired bicyclic peptides target the conserved influenza HA stem
A 2026 PNAS paper reports constrained bicyclic peptides, inspired by the FI6v3 antibody HCDR3, that bind the conserved hemagglutinin stem and neutralize multiple influenza A subtypes in vitro.
A PNAS paper describes a peptide-design approach that aims at a longstanding target: the conserved “stem” region of influenza hemagglutinin (HA).
What’s interesting here is the design logic. Instead of trying to discover a natural peptide, the authors graft key binding features of a broadly neutralizing antibody onto a chemically constrained bicyclic peptide scaffold.
What it is
The work uses a CLIPS (Chemical Linkage of Peptides onto Scaffolds) strategy to build constrained bicyclic peptides that mimic the binding mode of the FI6v3 broadly neutralizing antibody.
Specifically, the paper reports grafting the antibody’s heavy-chain CDR3 (HCDR3) onto functionalized small-molecule scaffolds.
What changed (the new result)
Previous peptide and small-molecule designs in this space often struggled to cover both major influenza A HA phylogenetic groups.
In this paper, the authors report peptides that:
- Bind HA from group 1 (including H1 and H5) and group 2 (including H3 and H7) in binding assays
- Neutralize several influenza A viruses in vitro (they mention H1N1, H5N1, and H7N3)
- Have a crystal structure showing a bicyclic peptide engaging HA in a way that “faithfully mimics” FI6v3 at the conserved stem epitope
Why it matters
If you want broadly protective influenza therapeutics, the HA stem is a natural target because it is more conserved than the head region.
Peptides can sit in a middle zone between small molecules and biologics:
- potentially easier to manufacture than antibodies
- potentially able to achieve binding geometries small molecules can’t
That said, in vitro neutralization is the start of the story, not the end.
What we know vs what we don’t
What we know (from this paper):
- The designed bicyclic peptides bind multiple HA subtypes across group 1 and 2.
- The authors report in vitro neutralization of several influenza A strains.
- Structural data supports the intended “antibody-mimic” binding mode.
What we don’t know yet:
- Whether these peptides can be delivered effectively in vivo (route, stability, tissue exposure).
- How they perform in animal models for prevention or treatment.
- Safety and off-target risk once you move beyond controlled assays.